Ascendis Pharma A/S
ASND
138 hedge funds and large institutions have $5.41B invested in Ascendis Pharma A/S in 2019 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 41 increasing their positions, 41 reducing their positions, and 13 closing their positions.
277% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 13
116% more capital invested
Capital invested by funds: $2.51B → $5.41B (+$2.91B)
59% more call options, than puts
Call options by funds: $230M | Put options by funds: $145M
46% more funds holding in top 10
Funds holding in top 10: 13 → 19 (+6)
34% more funds holding
Funds holding: 103 → 138 (+35)
3.98% more ownership
Funds ownership: 95.41% → 99.39% (+4%)
0% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$105M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$66.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.9M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$48.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$43.8M |
| 2 |
DM
Deerfield Management
New York
|
-$31.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$27.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$16.2M |
| 5 |
First Manhattan
New York
|
-$14.7M |
ASND Hedge Fund Activity: Q1 2019 in Review
138 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2019, worth a combined $5.41B — up 116% from $2.51B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ASND positions and 13 closed out — a net gain of 36 holders — while 41 added to existing stakes and 41 trimmed.
The largest buyer was Millennium Management, adding an estimated $105M. The largest seller was Sofinnova Investments, cutting an estimated $43.8M.
- 138 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2019, up from 103 in Q4 2018.
- Funds reported $5.41B of Ascendis Pharma A/S stock for Q1 2019, up 116% quarter-over-quarter.
- 49 funds opened new Ascendis Pharma A/S positions in Q1 2019 and 13 closed out, a net change of +36 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2019 was Millennium Management, an estimated $105M added.
- The largest Ascendis Pharma A/S seller in Q1 2019 was Sofinnova Investments, an estimated $43.8M sold.
Based on aggregated 13F filings for Q1 2019.